Effect of Udenafil on Portal Venous Pressure and Hepatic Fibrosis in Rats

Abstract

The purpose of this study was to investigate the therapeutic efficacy of udenafil (CAS 268203-93-6), a phosphodiesterase type 5 (PDE5) inhibitor, on bile duct ligation (BDL)-induced portal hypertension. Udenafil was given orally to rats at dose levels of 1, 5 or 25 mg/kg/day for 3 weeks in order to examine the chronic effect on portal venous pressure (PVP). Udenafil was also given orally to investigate the sequential change of PVP in BDL animals. The effect of udenafil on hepatic stellate cell activation and fibrotic change-related protein mRNA expression were examined. In a pharmacokinetic study, the pharmacokinetic parameters in sham-operated rats and BDL rats were compared. Three-week udenafil treatment decreased PVP by approximately 30% compared to the vehicle group. In a single oral administration study, the PVP of the udenafil treated group was lower than that of the control group throughout the experimental period. Compared to control, udenafil suppressed the expression of procollagen type I and α-smooth muscle actin mRNA. In the pharmacokinetic study, the AUC of udenafil in BDL rats was approximately 5 times higher than that in sham-operated rats. The results of this study suggest that udenafil has beneficial effects on portal hypertension and the effect may well be attributed to its anti-fibrogenic activity.

Key words

CAS 268203-93-6 - Fibrosis - Hepatic stellate cell - Phosphodiesterase type 5 inhibitor - Portal hypertension - Udenafil

• Literature

• 1 Garcia-Tsao G. Portal hypertension. Curr Opin Gastroenterol. 2006; 22: 254-262
• 2 Fiorucci S, Antonelli E, Tocchetti P, Morelli A. Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. Cardiovasc Drug Rev. 2004; 22: 135-46
• 3 Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol. 2003; 38 Supply (1) S54-68
• 4 Gonzalez-Abraldes J, Bosch J, Garcia-Pagan JC. Pharmacological treatment of portal hypertension. Curr Opin InvestigDrugs. 2001; 2: 1407-13
• 5 Loureiro-Silva MR, Iwakiri Y, Abraldes JG, Haq O, Groszmann RJ. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. J Hepatol. 2006; 44: 886-93
• 6 Deibert P, Schumacher YO, Ruecker G, Opitz OG, Blum HE, Rossle M et al. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver – results of a pilot study. Aliment Pharmacol Ther. 2006; 23: 121-8
• 7 Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am J Physiol. 1986; 251 (2 Pt 1) G176-80
• 8 Akimoto T, Hayashi N, Adachi M, Kobayashi N, Zhang XJ, Ohsuga M et al. Viability and plasma vitamin K levels in the common bile duct-ligated rats. Exp Anim. 2005; 54: 155-61
• 9 Braillon A, Brody MJ. A simple method for chronic cannulation of the portal vein in intact unrestrained rats. Am J Physiol. 1988; 255 (2 Pt 1) G191-3
• 10 Knook DL, Seffelaar AM, de Leeuw AM. Fat-storing cells of the rat liver. Their isolation and purification. Exp Cell Res. 1982; 139: 468-71
• 11 Kim J, Ji H, Kim SJ, Lee HW, Lee SS, Kim DS et al. Simultaneous determination of sildenafil and its active metabolite UK-103,320 in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2003; 32: 317-22
• 12 Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008; 65: 848-54
• 13 Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008; 5: 946-53
• 14 Kim JJ, Choi HK, Lee SW, Sur JK, Yang DY, Paick JS et al. A Phase III study to evaluate the efficacy and safety of Udenafil in Korean ED patient. Proceedings of the 12^th World Congress of the International Society for Sexual Medicine. 2006. Sep 17–21; Cairo, Egypt:
• 15 Sampson LJ, Hinton JM, Garland CJ. Evidence for expression and function of phosphodiesterase type 5 (PDE-V) in rat resistance arteries. Br J Pharmacol. 2001; 132: 13-7
• 16 Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999; 83: 3C-12C
• 17 Medina P, Segarra G, Martinez-Leon JB, Vila JM, Aldasoro M, Otero E et al. Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. Ann Thorac Surg. 2000; 70: 1327-31
• 18 Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis. 2001; 21: 337-49
• 19 Choi SM, Kim JE, Kang KK. Chronic treatment of DA-8159, a new phosphodiesterase type V inhibitor, attenuates endothelial dysfunction in stroke-prone spontaneously hypertensive rat. Life Sci. 2006; 78: 1211-6
• 20 Elinav E, Ali M, Bruck R, Brazowski E, Phillips A, Shapira Y et al. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology. 2009; 49: 278-86
• 21 Ueberham E, Löw R, Ueberham U, Schönig K, Bujard H, Gebhardt R. Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology. 2003; 37: 1067-78
• 22 Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol. 2002; 53 Suppl (1) 21S-30S